| pubmed-article:8729948 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8729948 | lifeskim:mentions | umls-concept:C1518932 | lld:lifeskim |
| pubmed-article:8729948 | lifeskim:mentions | umls-concept:C0279068 | lld:lifeskim |
| pubmed-article:8729948 | lifeskim:mentions | umls-concept:C0920321 | lld:lifeskim |
| pubmed-article:8729948 | lifeskim:mentions | umls-concept:C0050560 | lld:lifeskim |
| pubmed-article:8729948 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:8729948 | lifeskim:mentions | umls-concept:C0205269 | lld:lifeskim |
| pubmed-article:8729948 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8729948 | pubmed:dateCreated | 1996-10-21 | lld:pubmed |
| pubmed-article:8729948 | pubmed:abstractText | Forty-two patients with progressive solid tumors and brain tumors were entered in this Phase I study of the glutamine antagonist acivicin given intravenously over thirty minutes daily for five days. The major toxicities encountered were myelosuppression and central nervous system toxicity (nightmares and somnolence). The maximum tolerated dosage on this schedule was 26 mg/M2 daily for five days. Six patients including three patients with brain tumor had stable disease. | lld:pubmed |
| pubmed-article:8729948 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8729948 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8729948 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8729948 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8729948 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8729948 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8729948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8729948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8729948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8729948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8729948 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8729948 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8729948 | pubmed:issn | 0167-6997 | lld:pubmed |
| pubmed-article:8729948 | pubmed:author | pubmed-author:GriewSS | lld:pubmed |
| pubmed-article:8729948 | pubmed:author | pubmed-author:BernsteinMM | lld:pubmed |
| pubmed-article:8729948 | pubmed:author | pubmed-author:ViettiTT | lld:pubmed |
| pubmed-article:8729948 | pubmed:author | pubmed-author:BellBB | lld:pubmed |
| pubmed-article:8729948 | pubmed:author | pubmed-author:WhiteheadV... | lld:pubmed |
| pubmed-article:8729948 | pubmed:author | pubmed-author:DevineSS | lld:pubmed |
| pubmed-article:8729948 | pubmed:author | pubmed-author:DubowyRR | lld:pubmed |
| pubmed-article:8729948 | pubmed:author | pubmed-author:BaruchelSS | lld:pubmed |
| pubmed-article:8729948 | pubmed:author | pubmed-author:KretschmarCC | lld:pubmed |
| pubmed-article:8729948 | pubmed:author | pubmed-author:LangevinA MAM | lld:pubmed |
| pubmed-article:8729948 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8729948 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:8729948 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8729948 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8729948 | pubmed:pagination | 211-6 | lld:pubmed |
| pubmed-article:8729948 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:8729948 | pubmed:meshHeading | pubmed-meshheading:8729948-... | lld:pubmed |
| pubmed-article:8729948 | pubmed:meshHeading | pubmed-meshheading:8729948-... | lld:pubmed |
| pubmed-article:8729948 | pubmed:meshHeading | pubmed-meshheading:8729948-... | lld:pubmed |
| pubmed-article:8729948 | pubmed:meshHeading | pubmed-meshheading:8729948-... | lld:pubmed |
| pubmed-article:8729948 | pubmed:meshHeading | pubmed-meshheading:8729948-... | lld:pubmed |
| pubmed-article:8729948 | pubmed:meshHeading | pubmed-meshheading:8729948-... | lld:pubmed |
| pubmed-article:8729948 | pubmed:meshHeading | pubmed-meshheading:8729948-... | lld:pubmed |
| pubmed-article:8729948 | pubmed:meshHeading | pubmed-meshheading:8729948-... | lld:pubmed |
| pubmed-article:8729948 | pubmed:meshHeading | pubmed-meshheading:8729948-... | lld:pubmed |
| pubmed-article:8729948 | pubmed:meshHeading | pubmed-meshheading:8729948-... | lld:pubmed |
| pubmed-article:8729948 | pubmed:meshHeading | pubmed-meshheading:8729948-... | lld:pubmed |
| pubmed-article:8729948 | pubmed:meshHeading | pubmed-meshheading:8729948-... | lld:pubmed |
| pubmed-article:8729948 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8729948 | pubmed:articleTitle | A phase I study of acivicin in refractory pediatric solid tumors. A Pediatric Oncology Group study. | lld:pubmed |
| pubmed-article:8729948 | pubmed:affiliation | McGill University, Montreal, Canada. | lld:pubmed |
| pubmed-article:8729948 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8729948 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8729948 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8729948 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8729948 | lld:pubmed |
